Canaccord Genuity Group Issues Pessimistic Forecast for Prestige Consumer Healthcare (NYSE:PBH) Stock Price

Prestige Consumer Healthcare (NYSE:PBH) had its price objective cut by stock analysts at Canaccord Genuity Group from $86.00 to $72.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective points to a potential upside of 53.40% from the company’s current price.

Several other brokerages have also issued reports on PBH. Oppenheimer lowered Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Tuesday, April 21st. Finally, Jefferies Financial Group dropped their target price on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a research report on Friday, January 30th. Two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Prestige Consumer Healthcare has a consensus rating of “Hold” and a consensus price target of $70.75.

Prestige Consumer Healthcare Price Performance

Shares of PBH stock traded up $1.01 during trading on Friday, hitting $46.94. The company had a trading volume of 1,149,580 shares, compared to its average volume of 505,620. The stock’s 50-day moving average is $58.32 and its two-hundred day moving average is $61.49. The stock has a market capitalization of $2.22 billion, a price-to-earnings ratio of 11.99, a price-to-earnings-growth ratio of 1.55 and a beta of 0.40. The company has a quick ratio of 1.93, a current ratio of 3.11 and a debt-to-equity ratio of 0.58. Prestige Consumer Healthcare has a 52 week low of $42.62 and a 52 week high of $89.37.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). Prestige Consumer Healthcare had a return on equity of 11.62% and a net margin of 17.48%.The company had revenue of $281.62 million during the quarter, compared to the consensus estimate of $291.99 million. During the same period in the previous year, the company earned $1.32 EPS. Prestige Consumer Healthcare’s quarterly revenue was down 5.0% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. As a group, analysts predict that Prestige Consumer Healthcare will post 4.77 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, VP Jeffrey Zerillo sold 1,207 shares of the firm’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the transaction, the vice president directly owned 42,820 shares in the company, valued at $2,354,671.80. This trade represents a 2.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Lido Advisors LLC raised its holdings in Prestige Consumer Healthcare by 5.4% during the 4th quarter. Lido Advisors LLC now owns 3,778 shares of the company’s stock valued at $235,000 after buying an additional 192 shares during the last quarter. Profund Advisors LLC increased its position in shares of Prestige Consumer Healthcare by 3.2% in the third quarter. Profund Advisors LLC now owns 6,770 shares of the company’s stock valued at $422,000 after acquiring an additional 207 shares during the period. Cerity Partners LLC increased its position in shares of Prestige Consumer Healthcare by 5.9% in the second quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock valued at $310,000 after acquiring an additional 218 shares during the period. UMB Bank n.a. raised its stake in shares of Prestige Consumer Healthcare by 110.1% during the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after acquiring an additional 219 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in shares of Prestige Consumer Healthcare by 69.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock worth $35,000 after purchasing an additional 236 shares during the period. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).